Copy-number signatures and mutational processes in ovarian carcinoma
G. Macintyre, T. Goranova, D. De Silva, D. Ennis, A. M. Piskorz, M. Eldridge, D. Sie, L.-A. Lewsley, A. Hanif, C. Wilson, S. Dowson, R. M. Glasspool, M. Lockley, E. Brockbank, A. Montes, A. Walther, S. Sundar, R. Edmondson, G. D. Hall, A. Clamp, C. Gourley, M. Hall, C. Fotopoulou, H. Gabra, J. Paul, , J. D. Brenton
Abstract
Tumours with profound copy-number aberration elude molecular stratification due to their genomic complexity. By representing this complexity as a mixture of copy-number signatures, we provide molecular explanations for differing clinical outcomes. Here we present a method for copy-number signature identification, deriving eight signatures in 117 shallow whole-genome sequenced high-grade serous ovarian cancers (HGSOC), which validated on independent cohorts of 95 deep whole-genome sequenced, and 402 SNP array-profiled cases. Three copy-number signatures predicted longer overall survival, while the others predicted poorer outcome. We found evidence for the mutational processes giving rise to copy-number change for six of the eight signatures via correlations with other genomic features. Our results provide insights into the pathogenesis of HGSOC by uncovering multiple mutational processes that shape genomes following TP53 mutation. Importantly, our work shows that most HGSOC have a mixture of mutational processes suggesting that targeting a single mutator phenotype may be therapeutically suboptimal.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The genomic landscape of early stage ovarian high grade serous carcinoma
Z. Cheng, H. Mirza, … I. McNeish·bioRxiv·May 5, 2021
- Most commonly mutated genes in High Grade Serous Ovarian Carcinoma are nonessential for ovarian surface epithelial stem cell transformation
R. J. Yamulla, S. Nalubola, … J. C. Schimenti·bioRxiv·Jan 27, 2020
- The genomic trajectory of ovarian high grade serous carcinoma is determined in STIC lesions
Zhao Cheng, Darren P. Ennis, … Iain A. McNeish·The Journal of PathologyPeer-reviewed·Jul 2, 2024
- Multi-omic analysis of subtype evolution and heterogeneity in high-grade serous ovarian carcinoma
L. Geistlinger, S. Oh, … L. Waldron·bioRxiv·Jun 12, 2020
- Divergent trajectories to structural diversity impact patient survival in high grade serous ovarian cancer
A. Ewing, A. Meynert, … C. A. Semple·bioRxiv·Jan 12, 2024
- A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high grade serous ovarian cancer
P. Lo Riso, C. E. Villa, … G. Testa·bioRxiv·Nov 30, 2018